Bechis, S. K., A. G. Otsetov, R. Ge, Z. Wang, M. G. Vangel, C. L. Wu, S. Tabatabaei, and A. F. Olumi. 2015. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
Publications
2015
2014
Yang, H., X. Chen, X. Wang, Y. Li, S. Chen, X. Qian, R. Wang, et al. 2014. Inhibition of PP2A Activity Confers a TRAIL-Sensitive Phenotype During Malignant Transformation.
Rodríguez, D., G. W. Barrisford, A. Sanchez, M. A. Preston, E. I. Kreydin, and A. F. Olumi. 2014. Primary Spermatic Cord Tumors: Disease Characteristics, Prognostic Factors, and Treatment Outcomes.
Rodríguez, D., M. A. Preston, G. W. Barrisford, A. F. Olumi, and A. S. Feldman. 2014. Clinical Features of Leiomyosarcoma of the Urinary Bladder: Analysis of 183 Cases.
Xu, R., N. Horick, F. J. McGovern, D. M. Dahl, A. S. Feldman, M. L. Blute, A. F. Olumi, and M. D. Michaelson. 2014. Prognostic Significance of Indeterminate Lung Nodules in Renal Cell Carcinoma.
Preston, M. A., A. H. Riis, V. Ehrenstein, R. H. Breau, J. L. Batista, A. F. Olumi, L. A. Mucci, H. O. Adami, and H. T. Sørensen. 2014. Metformin Use and Prostate Cancer Risk.
Preston, M. A., K. M. Wilson, S. C. Markt, R. Ge, C. Morash, M. J. Stampfer, M. Loda, E. Giovannucci, L. A. Mucci, and A. F. Olumi. 2014. 5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer.
Aizer, A. A., J. J. Paly, M. D. Michaelson, S. K. Rao, P. L. Nguyen, I. D. Kaplan, A. Niemierko, A. F. Olumi, and J. A. Efstathiou. 2014. Medical Oncology Consultation and Minimization of Overtreatment in Men With Low-Risk Prostate Cancer.
Bechis, S. K., A. G. Otsetov, R. Ge, and A. F. Olumi. 2014. Personalized Medicine for the Management of Benign Prostatic Hyperplasia.
2013
Gershman, B., D. M. Dahl, A. F. Olumi, R. H. Young, W. S. McDougal, and C. L. Wu. 2013. Smaller Prostate Gland Size and Older Age Predict Gleason Score Upgrading.